Literature DB >> 20455858

CSPG4 in cancer: multiple roles.

X Wang1, Y Wang, L Yu, K Sakakura, C Visus, J H Schwab, C R Ferrone, E Favoino, Y Koya, M R Campoli, J B McCarthy, A B DeLeo, S Ferrone.   

Abstract

Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight-Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455858     DOI: 10.2174/156652410791316977

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  52 in total

1.  Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Authors:  Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan
Journal:  Clin Cancer Res       Date:  2013-09-10       Impact factor: 12.531

Review 2.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Authors:  Matthew A Price; Leah E Colvin Wanshura; Jianbo Yang; Jennifer Carlson; Bo Xiang; Guiyuan Li; Soldano Ferrone; Arkadiusz Z Dudek; Eva A Turley; James B McCarthy
Journal:  Pigment Cell Melanoma Res       Date:  2011-12       Impact factor: 4.693

Review 3.  Therapeutic targets of triple-negative breast cancer: a review.

Authors:  Vinayak S Jamdade; Nikunj Sethi; Nitin A Mundhe; Parveen Kumar; Mangala Lahkar; Neeraj Sinha
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

4.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

Review 5.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

6.  T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Authors:  Claudia Geldres; Barbara Savoldo; Valentina Hoyos; Ignazio Caruana; Ming Zhang; Eric Yvon; Michele Del Vecchio; Chad J Creighton; Michael Ittmann; Soldano Ferrone; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

7.  Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.

Authors:  Ali Salanti; Thomas M Clausen; Mette Ø Agerbæk; Nader Al Nakouzi; Madeleine Dahlbäck; Htoo Zarni Oo; Sherry Lee; Tobias Gustavsson; Jamie R Rich; Bradley J Hedberg; Yang Mao; Line Barington; Marina A Pereira; Janine LoBello; Makoto Endo; Ladan Fazli; Jo Soden; Chris K Wang; Adam F Sander; Robert Dagil; Susan Thrane; Peter J Holst; Le Meng; Francesco Favero; Glen J Weiss; Morten A Nielsen; Jim Freeth; Torsten O Nielsen; Joseph Zaia; Nhan L Tran; Jeff Trent; John S Babcook; Thor G Theander; Poul H Sorensen; Mads Daugaard
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

8.  Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.

Authors:  Fengying Tang; Megan S Lord; William B Stallcup; John M Whitelock
Journal:  J Biochem       Date:  2018-05-01       Impact factor: 3.387

Review 9.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

10.  Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Authors:  Thomas Mandel Clausen; Marina Ayres Pereira; Nader Al Nakouzi; Htoo Zarni Oo; Mette Ø Agerbæk; Sherry Lee; Maj Sofie Ørum-Madsen; Anders Riis Kristensen; Amal El-Naggar; Paul M Grandgenett; Jean L Grem; Michael A Hollingsworth; Peter J Holst; Thor Theander; Poul H Sorensen; Mads Daugaard; Ali Salanti
Journal:  Mol Cancer Res       Date:  2016-09-21       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.